{"id":2865,"date":"2014-10-30T15:43:07","date_gmt":"2014-10-30T07:43:07","guid":{"rendered":"http:\/\/wp.kmu.edu.tw\/rd\/?p=2865"},"modified":"2014-11-05T16:30:44","modified_gmt":"2014-11-05T08:30:44","slug":"%e8%ab%96%e6%96%87%e8%88%87%e5%ad%b8%e8%a1%93%e7%8d%8e%e5%8b%b5%e5%bf%83%e5%be%97%e5%88%86%e4%ba%ab","status":"publish","type":"post","link":"https:\/\/wp.kmu.edu.tw\/rd\/archives\/2865","title":{"rendered":"\u8ad6\u6587\u8207\u5b78\u8853\u734e\u52f5\u5fc3\u5f97\u5206\u4eab"},"content":{"rendered":"<p style=\"text-align: right\"><a href=\"http:\/\/wp.kmu.edu.tw\/rd\/archives\/2862\">\u56de\u7b2c0026\u671f\u4e3b\u9801<\/a><\/p>\n<h1><span style=\"font-size: x-large;color: #c10000\">\u4e00\u3001\u8ad6\u6587\u8207\u5b78\u8853\u734e\u52f5\u5fc3\u5f97\u5206\u4eab<\/span><\/h1>\n<p><a name=\"PaperRes1\"><\/a><\/p>\n<h1><span style=\"color: #0000ff\">\uff08\u4e00\uff09\u5b78\u8853\u734e\u52f5\u5fc3\u5f97\u5206\u4eab<\/span><\/h1>\n<ul>\n<li><span style=\"color: #3366ff\"><strong>2014\u5e74 \u884c\u653f\u9662\u79d1\u6280\u90e8\u5433\u5927\u7337\u5148\u751f\u7d00\u5ff5\u734e<br \/>\n\u5b78\u8853\u734e\u52f5\u2014\u91ab\u5b78\u7814\u7a76\u6240\u8a31\u96c5\u73b2\u526f\u6559\u6388<br \/>\n\u76ee\u524d\u7814\u7a76\u8457\u91cd\u65bc\u816b\u7624\u5fae\u74b0\u5883\u548c\u76f8\u95dc\u6a19\u9776\u6cbb\u7642\u7b56\u7565\u7684\u958b\u767c<\/strong><\/span><\/li>\n<\/ul>\n<ul>\n<li>\u816b\u7624\u9aa8\u8f49\u79fb\u63a2\u8a0e\uff1a<br \/>\n\u80ba\u764c\u7d30\u80de\u8868\u9054\u9ad8\u91cfIL-8\u5f8c\u63d0\u5347ostoclast\u5206\u5316\u548c\u6d3b\u6027\u63d0\u9ad8\u9020\u6210\u8755\u9aa8\u6027\u9aa8\u8f49\u79fb\uff1b\u800cIL-8\u7684\u63d0\u5347\u6e90\u81ea\u65bc\u80ba\u764c\u7d30\u80de\u7684microRNA 33a\u8868\u73fe\u53d7\u5230\u6291\u5236\uff0c\u4f7f\u5f97PTHrP\u5206\u5b50\u904e\u5ea6\u8868\u73fe\u7522\u751f\u6b63\u5411\u7684\u56de\u994b\u4f7f\u816b\u7624\u7d30\u80de\u8868\u9054\u904e\u591a\u7684IL-8\u3002\u53e6\u5916\uff0c\u816b\u7624\u7d30\u80de\u4e5f\u6703\u523a\u6fc0osteoblast\u5206\u6cccBMP-2\u548cCXCL5\uff0c\u9020\u6210\u816b\u7624\u7d30\u80de\u8f49\u79fb\u81f3\u80ba\u548c\u809d\u81df\u7b49\u3002\u7d66\u4e88CXCL5\u4e2d\u548c\u6027\u6297\u9ad4\u53ef\u4ee5\u6709\u6548\u7684\u964d\u4f4e\u816b\u7624\u7684\u8f49\u79fb\u3002<\/li>\n<\/ul>\n<ul>\n<li>\u816b\u7624\u514d\u75ab\u7cfb\u7d71\u4ea4\u4e92\u4f5c\u7528\uff1a<br \/>\n\u80ba\u764c\u7d30\u80de\u6703\u5206\u6cccgalectin-1\u9020\u6210\u6a39\u7a81\u7d30\u80de\u529f\u80fd\u4e0d\u5168\uff0c\u7121\u6cd5\u555f\u52d5\u6bd2\u6bba\u7d30\u80de\u7684T\u7d30\u80de\u53cd\u61c9\u3002\u53e6\u5916\u816b\u7624\u7d30\u80de\u4e5f\u6703\u9020\u6210\u816b\u7624\u6d78\u6f64\u4e4b\u6a39\u7a81\u7d30\u80de\u5206\u6ccc\u5404\u7a2e\u56e0\u5b50\uff0c\u5305\u62ecamphiregulin\u3001HB-EGF\u548cCXCL5\u7b49\u9020\u6210\u816b\u7624\u8f49\u79fb\u53ca\u63d0\u5347\u816b\u7624\u9020\u6210\u7684\u8755\u9aa8\u53cd\u61c9\u3002\u5229\u7528\u6297\u9ad4\u963b\u65b7\u4e0a\u8ff0\u5206\u5b50\u53ef\u6709\u6548\u964d\u4f4e\u816b\u7624\u7684\u8f49\u79fb\u4e26\u52a0\u5f37\u6a19\u9776\u85e5\u7269Iressa\u7684\u6cbb\u7642\u6548\u679c\u3002<\/li>\n<\/ul>\n<ul>\n<li>\u81f4\u764c\u57fa\u56e0\u767c\u73fe\uff1a<br \/>\n\u904e\u5ea6\u8868\u73fegalectin-1\u4e5f\u6703\u9020\u6210\u816b\u7624\u672c\u8eab\u4e4b\u79fb\u884c\u3001\u5165\u4fb5\u548c\u8f49\u79fb\u80fd\u529b\u7684\u63d0\u5347\uff1b\u6291\u5236galectin-1\u8868\u73fe\u4e0d\u4f46\u53ef\u4ee5\u964d\u4f4e\u816b\u7624\u8f49\u79fb\u7684\u80fd\u529b\uff0c\u4e5f\u53ef\u4ee5\u9632\u5835\u816b\u7624\u9020\u6210\u7684\u514d\u75ab\u5931\u80fd\u3002<\/li>\n<\/ul>\n<ul>\n<li>\u5f97\u734e\u611f\u8a00\uff1a<br \/>\n\u4eca\u5e74\u69ae\u73722014\u79d1\u6280\u90e8\u5433\u5927\u7337\u5148\u751f\u7d00\u5ff5\u734e\uff0c\u6df1\u611f\u69ae\u5e78\u3002<br \/>\n\u4f46\u9019\u500b\u734e\u9805\u4e26\u975e\u5c0d\u6211\u500b\u4eba\u7684\u80af\u5b9a\uff0c\u56e0\u70ba\u5728\u9019\u69ae\u8000\u4e4b\u5f8c\u5305\u542b\u8a31\u591a\u6210\u5c31\u7684\u529b\u91cf\u3002\u611f\u8b1d\u79d1\u6280\u90e8\u7d93\u8cbb\u548c\u76f8\u95dc\u7814\u7a76\u8cc7\u6e90\u7684\u63d0\u4f9b\uff1b\u611f\u8b1d\u9ad8\u96c4\u91ab\u5b78\u5927\u5b78\u5929\u7136\u85e5\u7269\u7814\u7a76\u6240\u548c\u91ab\u5b78\u7814\u7a76\u6240\u5e2b\u9577\u4e00\u8def\u7684\u63d0\u651c\uff0c\u5553\u8499\u6211\u4e26\u6a39\u7acb\u6700\u4f73\u5178\u7bc4\uff1b\u611f\u8b1d\u9ad8\u91ab\u5927\u548c\u7814\u7a76\u5718\u968a\u63d0\u4f9b\u8a31\u591a\u7814\u7a76\u8cc7\u6e90\uff0c\u624d\u5f97\u4ee5\u5c07\u7d19\u4e0a\u7684\u5be6\u9a57\u5047\u8a2d\u4e00\u4e00\u9a57\u8b49\uff1b\u4ea6\u611f\u8b1d\u6240\u6709\u5b78\u751f\u548c\u7814\u7a76\u5925\u4f34\u7684\u52aa\u529b\uff0c\u65b9\u80fd\u5f9e\u6559\u5b78\u548c\u8a0e\u8ad6\u88e1\u6fc0\u76ea\u51fa\u8a31\u591a\u60f3\u6cd5\uff0c\u5373\u6240\u8b02\u6559\u5b78\u76f8\u9577\u3002\u6700\u5f8c\u8981\u611f\u8b1d\u5bb6\u4eba\u9577\u4e45\u4ee5\u4f86\u7121\u79c1\u7684\u652f\u6301\u8207\u5305\u5bb9\uff0c\u9ad4\u8ad2\u7e3d\u662f\u8d85\u6642\u5de5\u4f5c\u7121\u6cd5\u966a\u4f34\u4f60\u5011\u7684\u6211\uff0c\u4e5f\u6c38\u9060\u5728\u5931\u6557\u632b\u6298\u7684\u9ed1\u6697\u4e2d\u70ba\u6211\u9ede\u4e0a\u6eab\u6696\u7684\u71c8\uff0c\u505a\u6211\u6700\u5f37\u5927\u7684\u5f8c\u76fe\u3002<br \/>\n\u80fd\u5c07\u81ea\u5df1\u7684\u8208\u8da3\uff0c\u8b8a\u6210\u4e00\u9805\u5de5\u4f5c\uff0c\u4e26\u5728\u5176\u4e2d\u8ca2\u737b\u5df1\u529b\uff0c\u5df2\u7d93\u662f\u4eba\u751f\u6700\u5927\u7684\u78ba\u5e78\u4e86\uff0c\u9084\u80fd\u7372\u5f97\u5927\u5bb6\u5c0d\u6211\u7684\u683d\u57f9\u548c\u80af\u5b9a\uff0c\u8877\u5fc3\u611f\u6fc0\u3002\u671f\u8a31\u81ea\u5df1\u80fd\u7e7c\u7e8c\u9ed8\u9ed8\u8015\u8018\uff0c\u8ca2\u737b\u6240\u5b78\uff0c\u4e26\u5c07\u51b7\u51b7bench\u4e0a\u64e6\u51fa\u6240\u6709\u7684\u611f\u52d5\u548c\u71b1\u5ff1\u5f80\u4e0b\u50b3\u905e\u3002\u5728\u672a\u4f86\u7684\u5b78\u8853\u751f\u6daf\u4e2d\uff0c\u5e0c\u671b\u80fd\u57f9\u80b2\u51fa\u66f4\u591a\u6709\u60f3\u6cd5\u4e14\u9858\u610f\u6295\u5165\u7814\u7a76\u7684\u9752\u5e74\u5b78\u5b50\u3002<\/li>\n<\/ul>\n<h1><span style=\"color: #0000ff\">\uff08\u4e00\uff09\u8ad6\u6587<\/span><\/h1>\n<p><a name=\"PaperRes2\"><\/a><\/p>\n<ul>\n<li><span style=\"color: #3366ff\">\u984c\u76ee\uff1a<strong><br \/>\nSustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.<br \/>\n<\/strong><\/span><\/li>\n<\/ul>\n<ul>\n<li>\u4f5c\u8005\uff1aYu ML1, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ; Taiwan Liver-Net Consortium. Hepatology. 2013 Jun;57(6):2135-42. doi: 10.1002\/hep.26266. Epub 2013 Apr 26.<\/li>\n<\/ul>\n<ul>\n<li>Patients dually infected with hepatitis C virus (HCV)\/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients. Yet, there is a similar rate of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patients compared with HCV-monoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate. The durability of hepatitis C and B clearance in coinfected patients was investigated in a 5-year follow-up study. Patients with active HCV genotype 1, both HBV-coinfected (n = 97) and HBV-monoinfected (n = 110), underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin. In patients with active HCV genotype 2 or 3, both HBV-coinfected (n = 64) and monoinfected (n = 50) patients underwent 24-week combination therapy. A total of 295 (91.9%) patients completed treatment and 24 weeks posttreatment follow-up; 264 (89.5%) patients agreed to receive additional follow-up for up to 5 years after the end of treatment. After a median follow-up of 4.6 \u00b1 1.0 years, six of the 232 patients achieving SVR developed HCV RNA reappearance, including five HCV genotype 1\/HBV-coinfected patients and one HCV genotype 2\/3-monoinfected patient. Subgenomic analysis of the HCV core gene indicated that five patients developed delayed recurrence of HCV infection. Overall, the cumulative recurrence rate of HCV infection was 2.3% (0.4%\/year; 95% confidence interval [CI], 0.9%-5.5%). The cumulative HBsAg seroclearance rate was 30.0% (95% CI, 21.5%-42.0%); with 33.1% (95% CI, 21.8%-50.1%) in the 48-week combination therapy group and 24.3% (95% CI, 13.7%-42.9%) in the 24-week therapy group.<br \/>\nCONCLUSION:<br \/>\nPeginterferon alfa-2a and ribavirin therapy provides good HCV SVR durability and a high accumulative HBsAg seroclearance rate in patients who are coinfected with HCV and HBV. (HEPATOLOGY 2013;).<\/li>\n<\/ul>\n<p><a name=\"PaperRes3\"><\/a><\/p>\n<ul>\n<li><span style=\"color: #3366ff\">\u984c\u76ee\uff1a<strong><br \/>\nManagement of gastric cancer in Asia: resource-stratified guidelines<br \/>\n<\/strong><\/span><\/li>\n<\/ul>\n<ul>\n<li>\u4f5c\u8005\uff1aShen L1, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT Lancet Oncol. 2013 Nov;14(12):e535-47. doi: 10.1016\/S1470-2045(13)70436-4(\u85e5\u5b78\u9662 \u694a\u5955\u99a8\u6559\u6388\u63d0\u4f9b)<\/li>\n<\/ul>\n<ul>\n<li>Gastric cancer is the fourth most common cancer globally, and is the second most common cause of death from cancer worldwide. About three-quarters of newly diagnosed cases in 2008 were from Asian countries. With a high mortality-to-incidence ratio, management of gastric cancer is challenging. We discuss evidence for optimum management of gastric cancer in aspects of screening and early detection, diagnosis, and staging; endoscopic and surgical intervention; and the concepts of perioperative, postoperative, and palliative chemotherapy and use of molecularly targeted therapy. Recommendations are formulated on the basis of the framework provided by the Breast Health Global Initiative, using the categories of basic, limited, enhanced, and maximum level. We aim to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries.<br \/>\nCopyright \u00a9 2013 Elsevier Ltd. All rights reserved.<br \/>\nComment in<br \/>\nEvidence-based methods to address disparities in global cancer control: the development of guidelines in Asia. [Lancet Oncol. 2013]\n\u8eab\u70ba\u4e00\u500b\u5927\u5b78\u6559\u5e2b\uff0c\u96a8\u6642\u6ce8\u610f\u81ea\u5df1\u7684\u7814\u7a76\u8868\u73fe\uff0c\u5e38\u5e38\u662f\u4e00\u80a1\u7121\u6cd5\u5ffd\u8996\u7684\u5de8\u5927\u7684\u58d3\u529b\uff0c\u96d6\u7136\u6709\u4eba\u8aaa\u570b\u969b\u671f\u520a\u7684\u5f71\u97ff\u6307\u6578\uff08IF, impact factor\uff09\u4e26\u4e0d\u4ee3\u8868\u7814\u7a76\u7684\u5168\u90e8\uff0c\u800c\u4e14\u300c\u597d\u300d\u7684\u7814\u7a76\u6216\u662f\u300c\u91cd\u8981\u300d\u7684\u7814\u7a76\u4e5f\u53ef\u4ee5\u6709\u4e0d\u540c\u65b9\u5f0f\u7684\u5b9a\u7fa9\uff0c\u7136\u800c\u73fe\u5be6\u5c64\u9762\u6bcf\u7bc7\u767c\u8868\u6587\u7ae0\u7684impact factor\u591a\u5c11\uff0c\u591a\u534a\u9084\u662f\u7b2c\u4e00\u500b\u88ab\u554f\u7684\u554f\u984c\u3002<br \/>\n\u81ea\u5df1\u56e0\u70ba\u4e00\u7bc7Lancet Oncology\u7684\u6587\u7ae0\uff0c\u6210\u70ba\u5168\u6821\u53bb\u5e74\u5ea6IF\u6700\u9ad8\u7684\u4f5c\u8005\u6642\uff0c\u5fc3\u4e2d\u4e0d\u7121\u60f6\u6050\uff0c\u7b2c\u4e00\u6642\u9593\u6025\u8457\u8981\u8ddf\u5225\u4eba\u6f84\u6e05\uff0c\u9019\u662f\u7bc7invited review paper\uff0c\u800c\u6211\u53ea\u662f\u6709\u5e78\u88ab\u570b\u5bb6\u885b\u751f\u7814\u7a76\u9662\u764c\u75c7\u7814\u7a76\u6240\u9673\u7acb\u5b97\u6240\u9577\u9080\u8acb\u53c3\u8207\u64b0\u5beb\u5718\u968a\u800c\u5df2\uff1b\u56de\u60f3\u8d77\u4f86\u7e3d\u89ba\u5f97\u81ea\u5df1\u5e78\u904b\u591a\u65bc\u52aa\u529b\uff0c\u540c\u6642\u4e5f\u5f88\u6176\u5e78\u81ea\u5df1\u5e7e\u5e74\u4f86\u7d2f\u7a4d\u7684\u7814\u7a76\u7d93\u9a57\uff0c\u4e5f\u7b97\u662f\u4e0d\u8ca0\u6240\u6258\u5b8c\u6210\u4f7f\u547d\u3002<br \/>\n\u9019\u7bc7\u53d7\u9080\u64b0\u5beb\u7684\u6587\u737b\u56de\u9867\uff0c\u4e3b\u8981\u7684\u4efb\u52d9\u662f\u5e0c\u671b\u5f59\u6574\u4e9e\u6d32\u5730\u5340\u80c3\u764c\u60a3\u8005\u6cbb\u7642\u7684\u5171\u8b58\uff0c\u4e26\u4e14\u6240\u6b78\u7d0d\u7684\u7d50\u8ad6\u8207\u6cbb\u7642\u5efa\u8b70\uff0c\u9700\u8981\u8003\u616e\u5230\u4e0d\u540c\u5730\u5340\u91ab\u7642\u8cc7\u6e90\u7684\u554f\u984c\uff1b\u80c3\u764c\u662f\u5168\u4e16\u754c\u7b2c\u56db\u5927\u5e38\u898b\u7684\u764c\u75c7\uff0c\u4f9d\u64daWHO\u57282008\u5e74\u7684\u8cc7\u6599\u986f\u793a\uff0c\u6709\u56db\u5206\u4e4b\u4e09\u7684\u60a3\u8005\u662f\u5728\u4e9e\u6d32\uff0c\u5176\u4e2d\u9664\u4e86\u65e5\u672c\u8207\u97d3\u570b\u5728\u65e9\u671f\u767c\u73fe\u65b9\u9762\u9817\u5177\u6210\u6548\uff0c\u57fa\u672c\u4e0a\u5927\u90e8\u5206\u570b\u5bb6\u80c3\u764c\u7684\u6b7b\u4ea1\u7387\u5c0d\u767c\u751f\u7387\u6bd4\u503c(mortality-to-incidence ratio)\u591a\u9ad8\u90540.8\uff0c\u56e0\u6b64\u60a3\u8005\u7684\u6cbb\u7642\u7b56\u7565\u662f\u500b\u570b\u969b\u9593\u5c24\u5176\u662f\u4e9e\u6d32\u53d7\u5230\u95dc\u6ce8\u7684\u554f\u984c\uff0c\u570b\u969b\u9593\u96d6\u5df2\u6709\u767c\u8868\u4e00\u4e9b\u80c3\u764c\u6cbb\u7642\u7b56\u7565\u7684\u6e96\u5247\u6216\u5171\u8b58\uff0c\u4f46\u662f\u4ee5\u4e9e\u6d32\u5730\u5340\u70ba\u4e3b\u7684\u5171\u8b58\u5247\u5c1a\u672a\u7522\u751f\u3002\u9673\u7acb\u5b97\u6240\u9577\u53d7\u5230Lancet Oncology\u96dc\u8a8c\u7684\u9080\u8acb\u7d44\u6210\u4e00\u500b\u64b0\u5beb\u5718\u968a\uff0c\u53f0\u7063\u7684\u5718\u968a\u9084\u5305\u62ec\u53f0\u5927\u7684\u8449\u5764\u8f1d\u6559\u6388\u3001\u6210\u5927\u7684\u6c88\u5ef6\u76db\u6559\u6388\u53ca\u9ad8\u91ab\u7684\u80e1\u6643\u9cf4\u91ab\u5e2b\uff0c\u570b\u5916\u9084\u9080\u8acb\u4e86\u6fb3\u6d32\u3001\u4e2d\u570b\u3001\u5370\u5ea6\u3001\u65e5\u672c\u3001\u97d3\u570b\u7b49\u570b\u7684\u80c3\u764c\u816b\u7624\u5c08\u5bb6(oncologist)\uff1b\u64b0\u5beb\u7684\u6e96\u5099\u5de5\u4f5c\u4e3b\u8981\u662f\u53f0\u7063\u7684\u5718\u968a\u8ca0\u8cac\uff0c\u5f9e\u5f59\u6574\u5404\u570b\u7684\u80c3\u764c\u6cbb\u7642\u6e96\u5247\u53ca\u570b\u969b\u9593\u5df2\u767c\u8868\u7684\u5171\u8b58\u6216\u901a\u5247\u958b\u59cb\u6574\u7406\uff0c\u5148\u5c31\u6cbb\u7642\u7684\u968e\u6bb5\u8207\u7a2e\u985e\u8a02\u51fa\u8981\u6574\u7406\u7684\u9805\u76ee\uff0c\u4e3b\u8981\u662f\u628a\u6587\u5b57\u7684\u63cf\u8ff0\u7528\u8868\u683c\u9805\u76ee\u7684\u65b9\u5f0f\u7d71\u6574\uff0c\u6240\u6574\u7406\u51fa\u7684\u9805\u76ee\u8981\u80fd\u9069\u7528\u65bc\u5404\u570b\u7684\u5167\u5bb9\uff0c\u63a5\u8457\u53f0\u7063\u7684\u5718\u968a\u5728\u7d30\u8b80\u5176\u4ed6\u570b\u5bb6\u7576\u5730\u7684\u80c3\u764c\u6cbb\u7642\u6e96\u5247\u5f8c\uff0c\u52a0\u4ee5\u6b78\u7d0d\uff0c\u671f\u9593\u4f86\u4f86\u56de\u56de\u8207\u5404\u570b\u5c08\u5bb6\u9032\u884c\u586b\u8868\u4fee\u6539\u8207\u8a0e\u8ad6\uff0c\u6700\u5f8c\u518d\u7531\u7d71\u6574\u7684\u9805\u76ee\u4f9d\u64da\u91ab\u7642\u8cc7\u6e90\u7684\u7a0b\u5ea6\u505a\u5206\u985e\u3002<br \/>\n\u770b\u5230\u81ea\u5df1\u7684\u540d\u5b57\u5370\u5728Lancet Oncology\u7684\u6587\u7ae0\u4e2d\u771f\u7684\u5f88\u611f\u52d5\u3001\u5f88\u958b\u5fc3\uff0c\u5728\u6574\u500b\u6587\u7ae0\u64b0\u5beb\u671f\u9593\u7121\u6578\u6b21\u7684\u8a0e\u8ad6\u53ca\u8207\u64b0\u5beb\u5718\u968a\u7684\u4fe1\u4ef6\u5f80\u4f86\uff0c\u90fd\u662f\u5f88\u6709\u50f9\u503c\u7684\u7d93\u6b77\uff0c\u81ea\u5df1\u6b78\u7d0d\u6574\u7406\u8cc7\u6599\u7684\u5c08\u9577\u80fd\u5920\u5728\u5718\u968a\u4e2d\u767c\u63ee\uff0c\u8457\u5be6\u6709\u5f88\u5927\u7684\u6210\u5c31\u611f\u3002<br \/>\n\u7531\u65bc\u6211\u500b\u4eba\u7684\u5c08\u9577\u662f\u7d71\u8a08\u5206\u6790\uff0c\u9019\u5e7e\u5e74\u4f86\u7814\u7a76\u65b9\u5411\u4e5f\u591a\u4ee5\u81e8\u5e8a\u91ab\u5b78\u85e5\u5b78\u9818\u57df\u70ba\u4e3b\uff0c\u7528\u4f86\u7814\u7a76\u7684\u65b9\u6cd5\u4e3b\u8981\u9084\u662f\u8cc7\u6599\u7684\u5f59\u6574\u8207\u5206\u6790\uff0c\u6211\u7684\u7814\u7a76\u5ba4\u4e0d\u50cf\u4e00\u822c\u5370\u8c61\u4e2d\u7684\u5be6\u9a57\u5ba4\uff0c\u6c92\u6709\u6602\u8cb4\u5100\u5668\u3001\u4e5f\u6c92\u6709\u74f6\u74f6\u7f50\u7f50\uff0c\u9664\u4e86\u96fb\u8166\u5916\u9084\u662f\u96fb\u8166\uff0c\u662f\u4fd7\u7a31\u7684\u300cdry lab\u300d\u3002\u96d6\u7136\u5728\u7d71\u8a08\u53ca\u8cc7\u6599\u5206\u6790\u7684\u904e\u7a0b\u4e2d\uff0c\u540c\u6a23\u6709\u8403\u53d6\u3001\u6709\u5206\u6790\u5206\u96e2\u3001\u4e5f\u9700\u8981\u9a57\u8b49\u78ba\u8a8d\uff0c\u5de5\u5e8f\u6b65\u9a5f\u4e00\u6a23\u90fd\u4e0d\u80fd\u5c11\uff0c\u904e\u7a0b\u4e2d\u4e5f\u662f\u9700\u8981\u4e00\u5b9a\u7684\u5c08\u696d\u8207\u7d93\u9a57\uff0c\u7136\u800c\u5728\u73fe\u5be6\u5c64\u9762\u662f\u4e0d\u592a\u6703\u8b93\u4eba\u5370\u8c61\u6df1\u523b\uff0c\u66f4\u5225\u8aaa\u6703\u806f\u60f3\u5230 high impact factor \u8ad6\u6587\u7522\u51fa\u3002\u662f\u5c0d\u81ea\u5df1\u662f\u671f\u8a31\u4e5f\u597d\u3001\u662f\u4e0d\u670d\u6c23\u4e5f\u597d\uff0c\u505adry lab\u7814\u7a76\u96e3\u9053\u8207high IF\u7121\u7de3\u55ce\uff1f\u5982\u679c\u5c0d\u81ea\u5df1\u6709\u4e00\u7d72\u7d72\u81ea\u8c6a\u6216\u662f\u671f\u8a31\uff0c\u90a3\u5c31\u662f\u7814\u7a76\u9818\u57df\u4e0d\u8a72\u6703\u6709\u4e3b\u6d41\u6216\u975e\u4e3b\u6d41\uff0c\u53ea\u8981\u5920\u7528\u5fc3\uff0c\u6c92\u6709\u4e0d\u53ef\u80fd\u7684\u4e8b\uff01<\/li>\n<\/ul>\n<p style=\"text-align: right\"><a href=\"http:\/\/wp.kmu.edu.tw\/rd\/archives\/2862\">\u56de\u7b2c0026\u671f\u4e3b\u9801<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u56de\u7b2c0026\u671f\u4e3b\u9801 \u4e00\u3001\u8ad6\u6587\u8207\u5b78\u8853\u734e\u52f5\u5fc3\u5f97\u5206\u4eab \uff08\u4e00\uff09\u5b78\u8853\u734e\u52f5\u5fc3\u5f97\u5206\u4eab 2014 &hellip; <a href=\"https:\/\/wp.kmu.edu.tw\/rd\/archives\/2865\">\u95b1\u8b80\u5168\u6587 <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-2865","post","type-post","status-publish","format-standard","hentry","category-34"],"_links":{"self":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/2865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/comments?post=2865"}],"version-history":[{"count":2,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/2865\/revisions"}],"predecessor-version":[{"id":2894,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/2865\/revisions\/2894"}],"wp:attachment":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/media?parent=2865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/categories?post=2865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/tags?post=2865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}